| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Molly Harper is Director at CPRX. Molly Harper's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider.
Our model assigns Molly Harper a below-average insider score of 31/100, based on 4 past trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -35.8%.
Molly Harper has 16 Form 4 filings on record from December 2022 to December 2025, all as Director at Catalyst Pharmaceuticals (CPRX), 2022–2025.
The 27 reported transactions were 12 option exercises, 8 option or other derivative awards and 7 open-market sales.
Counted by filing, the open-market trades come to no purchases and 4 sales worth about $1.3M.
The largest open-market sale was 26,746 shares of CPRX at an average $23.25 on December 12, 2025, about $622K.
None of the 4 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | CPRX Catalyst Pharmaceuticals, Inc. | Director | Sale+OE | 26,746 | $23.25 | $621,920.29 | -91.9% | -1.0% | - | |
| Nov 27, 2024 | CPRX Catalyst Pharmaceuticals, Inc. | Director | Sale+OE | 17,500 | $22.00 | $385,000.00 | - | -6.9% | +4.8% | |
| Jun 3, 2024 | CPRX Catalyst Pharmaceuticals, Inc. | Director | Sell | 5,333 | $16.30 | $86,949.23 | -100% | +22.0% | +54.0% | |
| Dec 15, 2023 | CPRX Catalyst Pharmaceuticals, Inc. | Director | Sale+OE | 14,000 | $14.39 | $201,420.00 | - | +12.6% | +48.7% |